ATE254123T1 - Benzazolderivate und ihre verwendung als jnk modulatoren - Google Patents

Benzazolderivate und ihre verwendung als jnk modulatoren

Info

Publication number
ATE254123T1
ATE254123T1 AT00991229T AT00991229T ATE254123T1 AT E254123 T1 ATE254123 T1 AT E254123T1 AT 00991229 T AT00991229 T AT 00991229T AT 00991229 T AT00991229 T AT 00991229T AT E254123 T1 ATE254123 T1 AT E254123T1
Authority
AT
Austria
Prior art keywords
benzazole derivatives
jnk modulators
jnk
modulators
benzazole
Prior art date
Application number
AT00991229T
Other languages
English (en)
Inventor
Serge Halazy
Dennis Church
Montserrat Camps
Pascale Gaillard
Jean-Pierre Gotteland
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE254123T1 publication Critical patent/ATE254123T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00991229T 1999-12-24 2000-12-20 Benzazolderivate und ihre verwendung als jnk modulatoren ATE254123T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99811207A EP1110957A1 (de) 1999-12-24 1999-12-24 Benzazolderivate und ihre Verwendung als JNK Modulatoren
PCT/EP2000/013006 WO2001047920A1 (en) 1999-12-24 2000-12-20 Benzazole derivatives and their use as jnk modulators

Publications (1)

Publication Number Publication Date
ATE254123T1 true ATE254123T1 (de) 2003-11-15

Family

ID=8243214

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00991229T ATE254123T1 (de) 1999-12-24 2000-12-20 Benzazolderivate und ihre verwendung als jnk modulatoren

Country Status (32)

Country Link
US (2) US7259162B2 (de)
EP (2) EP1110957A1 (de)
JP (1) JP4782344B2 (de)
KR (2) KR100736012B1 (de)
CN (1) CN1252067C (de)
AR (1) AR029215A1 (de)
AT (1) ATE254123T1 (de)
AU (1) AU780241B2 (de)
BG (1) BG65986B1 (de)
BR (1) BR0016911A (de)
CA (1) CA2394809C (de)
CZ (1) CZ300984B6 (de)
DE (1) DE60006580T2 (de)
DK (1) DK1240164T3 (de)
EA (1) EA007152B1 (de)
EE (1) EE05456B1 (de)
ES (1) ES2206351T3 (de)
HR (1) HRP20020496B1 (de)
HU (1) HU229625B1 (de)
IL (2) IL150346A0 (de)
MX (1) MXPA02006242A (de)
NO (1) NO323146B1 (de)
NZ (1) NZ519423A (de)
PL (1) PL356634A1 (de)
PT (1) PT1240164E (de)
RS (1) RS51008B (de)
SI (1) SI1240164T1 (de)
SK (1) SK287546B6 (de)
TR (2) TR200302320T4 (de)
UA (1) UA73151C2 (de)
WO (1) WO2001047920A1 (de)
ZA (1) ZA200204427B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002255263B2 (en) 2001-04-16 2006-12-14 Eisai R&D Management Co., Ltd. Novel 1H-indazole compound
ATE419247T1 (de) 2001-07-23 2009-01-15 Serono Lab Arylsulfonamidderivate als hemmer c-jun- terminaler kinasen (jnk)
ES2268127T3 (es) * 2001-12-07 2007-03-16 Applied Research Systems Ars Holding N.V. Derivados de benzazol para el tratamiento de esclerodermia.
SI1501828T1 (sl) * 2002-04-25 2008-04-30 Labortories Serono Sa Piperazin-benzotiazoli kot sredstva za zdravljenje cerebralnih ishemicnih motenj/okvar ali motenj/okvar centralnega živcnega sistema
CN1656079A (zh) 2002-05-31 2005-08-17 卫材株式会社 吡唑化合物和含有该化合物的药物组合物
WO2003106455A1 (en) * 2002-06-14 2003-12-24 Applied Research Systems Ars Holding N.V. Azole methylidene cyanide derivatives and their use as protein kinase modulators
US7582429B2 (en) 2002-10-23 2009-09-01 University Of Utah Research Foundation Amplicon melting analysis with saturation dyes
EP1633363B1 (de) 2003-05-08 2012-11-07 Merck Serono SA Pyridinyl acetonitrile
DK1696909T3 (da) * 2003-09-12 2008-01-02 Serono Lab Benzothiazolderivater til behandling af diabetes
CA2534317A1 (en) * 2003-09-12 2005-03-24 Applied Research Systems Ars Holding N.V. Benzimidazole acetonitriles
WO2005026159A1 (en) * 2003-09-12 2005-03-24 Applied Research Systems Ars Holding N.V. Benzoxazole acetonitriles
CA2561907A1 (en) * 2004-04-08 2005-10-20 Applied Research Systems Ars Holding N.V. Composition comprising a jnk inhibitor and cyclosporin
US7387887B2 (en) * 2004-04-20 2008-06-17 University Of Utah Research Foundation Nucleic acid melting analysis with saturation dyes
US9657347B2 (en) 2004-04-20 2017-05-23 University of Utah Research Foundation and BioFire Defense, LLC Nucleic acid melting analysis with saturation dyes
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
HRP20080544T3 (hr) * 2004-11-17 2008-12-31 Ares Trading S.A. Formulacije benzotiazola i njihova uporaba
US7838522B2 (en) 2004-11-17 2010-11-23 Ares Trading S.A. Benzothiazole formulations and use thereof
RS52193B (sr) 2004-12-21 2012-10-31 Merck Serono Sa. Ciklični derivati sulfonil amina i njihova upotreba
CA2592154C (en) 2005-01-31 2014-03-18 Laboratoires Serono S.A. N-hydroxyamide derivatives and use thereof
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
BRPI0613042A2 (pt) * 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
EP1974013A2 (de) 2005-12-29 2008-10-01 Anthrogenesis Corporation Verbesserte zusammensetzung zum sammeln und zur konservierung von plazentastammzellen sowie verfahren zur verwendung der zusammensetzung
WO2007141224A2 (en) * 2006-06-02 2007-12-13 Laboratoires Serono Sa Jnk inhibitors for treatment of skin diseases
CN101541522B (zh) * 2006-08-28 2012-07-18 丹塞姆空气调节有限公司 用于制造热交换器的方法
EP2129775A1 (de) 2007-02-12 2009-12-09 Anthrogenesis Corporation Hepatocyten und chondrocyten aus adhärenten plazentastammzellen sowie cd34+, cd45- plazentastammzellenangereicherte zellpopulationen
MX2011001702A (es) * 2008-08-12 2011-04-28 Sirtris Pharmaceuticals Inc Benzoxazoles, benzotiazoles y analogos relacionados como moduladores de sirtuina.
JP5555239B2 (ja) 2008-09-29 2014-07-23 テリック，インコーポレイテッド キナーゼ阻害剤としての２−［１ｈ−ベンゾイミダゾール−２（３ｈ）−イリデン］−２−（ピリミジン−２−イル）アセトアミド及び２−［ベンゾチアゾール−２（３ｈ）−イリデン］−２−（ピリミジン−２−イル）アセトアミド
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
CN102199147A (zh) * 2011-03-19 2011-09-28 陕西合成药业有限公司 用于治疗的硝基咪唑衍生物
EP3443968A1 (de) 2011-06-01 2019-02-20 Celularity, Inc. Schmerzbehandlung mithilfe von stammzellen aus der plazenta
WO2014114186A1 (zh) * 2013-01-24 2014-07-31 山东亨利医药科技有限责任公司 Jnk抑制剂
EP3082422A4 (de) * 2013-12-20 2017-07-05 Biomed Valley Discoveries, Inc. Krebsbehandlungen unter verwendung von kombinationen aus typ-1-mek- und -erk-hemmern
KR101520378B1 (ko) * 2014-10-02 2015-05-26 (주)에프테크 습식 가스 스크러버의 배기유도장치
WO2016055517A1 (en) * 2014-10-08 2016-04-14 Institut National De La Sante Et De La Recherche Medicale (Inserm) Novel aminopyridine compounds useful as inhibitors of protein prenylation
JP6886165B2 (ja) * 2016-02-15 2021-06-16 国立大学法人山形大学 ガン抑制薬及び抗腫瘍剤、腫瘍再発防止剤、腫瘍発生予防剤

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2918369A (en) * 1956-06-15 1959-12-22 Gen Aniline & Film Corp Non-ionic benzimidazole cyanine dyes containing in alpha-position a cyano group on the methenyl chain
GB864131A (en) * 1957-07-17 1961-03-29 Ciba Ltd Benzimidazolyl-acetic acid derivatives
DE1963542A1 (de) 1969-12-18 1971-06-24 Siemens Ag Koppelfeldanordnung fuer Fernmelde-,insbesondere Fernsprechanlagen
JPS51123223A (en) * 1975-04-21 1976-10-27 Fuji Photo Film Co Ltd Process for producing condensation products
CH593954A5 (de) 1975-07-21 1977-12-30 Ciba Geigy Ag
US4933341A (en) * 1988-10-08 1990-06-12 Bayer Aktiengesellschaft Substituted 1,3,5-triazinetriones, for use against parasitic protozoa
EP0364765A3 (de) * 1988-10-08 1991-07-17 Bayer Ag Substituierte 1,3,5-Triazintrione, Verfahren zu ihrer Herstellung und ihre Verwendung gegen parasitäre Protozoen
US5523312A (en) * 1994-09-27 1996-06-04 Sterling Winthrop Inc. Antipicornaviral agents
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
JP4153574B2 (ja) * 1997-09-10 2008-09-24 トーアエイヨー株式会社 新規なピペリジン誘導体、その製造法およびそれを含有する循環器官用剤
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine

Also Published As

Publication number Publication date
KR20020072282A (ko) 2002-09-14
EA007152B1 (ru) 2006-08-25
CA2394809A1 (en) 2001-07-05
HU229625B1 (hu) 2014-03-28
US7470686B2 (en) 2008-12-30
CZ20022169A3 (cs) 2002-09-11
YU49202A (sh) 2006-01-16
CA2394809C (en) 2011-03-15
SK287546B6 (sk) 2011-01-04
IL150346A0 (en) 2002-12-01
CN1433414A (zh) 2003-07-30
AR029215A1 (es) 2003-06-18
HRP20020496B1 (hr) 2009-03-31
CN1252067C (zh) 2006-04-19
EE200200318A (et) 2003-10-15
DE60006580D1 (de) 2003-12-18
HK1055730A1 (en) 2004-01-21
IL150346A (en) 2010-12-30
EE05456B1 (et) 2011-08-15
DE60006580T2 (de) 2004-09-16
NZ519423A (en) 2004-04-30
TR200302320T4 (tr) 2004-01-21
BG106830A (bg) 2003-02-28
HUP0204557A3 (en) 2009-03-30
NO20022997L (no) 2002-06-21
WO2001047920A1 (en) 2001-07-05
US20030162794A1 (en) 2003-08-28
SI1240164T1 (en) 2004-04-30
EP1110957A1 (de) 2001-06-27
SK8982002A3 (en) 2002-10-08
KR20070047853A (ko) 2007-05-07
RS51008B (sr) 2010-10-31
AU3161601A (en) 2001-07-09
EP1240164A1 (de) 2002-09-18
HUP0204557A2 (en) 2003-05-28
AU780241B2 (en) 2005-03-10
NO20022997D0 (no) 2002-06-21
BR0016911A (pt) 2002-10-22
JP2003519142A (ja) 2003-06-17
ZA200204427B (en) 2004-02-03
US20070259892A1 (en) 2007-11-08
MXPA02006242A (es) 2003-01-28
EP1240164B1 (de) 2003-11-12
NO323146B1 (no) 2007-01-08
CZ300984B6 (cs) 2009-09-30
US7259162B2 (en) 2007-08-21
JP4782344B2 (ja) 2011-09-28
ES2206351T3 (es) 2004-05-16
TR200201509T2 (tr) 2002-09-23
DK1240164T3 (da) 2004-03-01
HRP20020496A2 (en) 2006-03-31
KR100736012B1 (ko) 2007-07-06
PT1240164E (pt) 2004-02-27
PL356634A1 (en) 2004-06-28
BG65986B1 (bg) 2010-08-31
EA200200708A1 (ru) 2003-02-27
UA73151C2 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
DE60006580D1 (de) Benzazolderivate und ihre verwendung als jnk modulatoren
DE60036803D1 (de) Arylmethyl-carbonylamino-thiazolderivate und ihre verwendung als antitumormittel
ATE252091T1 (de) Biaryl-oxa(thia)zolderivate und ihre verwendung als ppars modulatoren
DE50008597D1 (de) Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
DE60031513D1 (de) Phenyl- und pyridinyl-derivate verwendbar als neurokinin-1-antagonisten
DE60039539D1 (de) 4-aminopiperidin-derivate und ihre verwendung als arzneimittel
DE69926800D1 (de) Benzoheterozyklen und ihre verwendung als mek inhibitoren
DE59710422D1 (de) Acylmercapto-triazolyl-derivate und ihre verwendung als mikrobizide
DE59710580D1 (de) Thiocyano-triazolyl-derivate und ihre verwendung als mikrobizide
ATE398108T1 (de) Chinolinderivate und deren verwendung als 5-ht6 liganden
DE60041343D1 (de) Oxa- und thiazolderivate sowie ihre verwendung gegen diabetes und fettsucht
DE60016326D1 (de) Wasser-absorbierende Zusammensetzung und ihre Verwendung
DE60027927D1 (de) Harzstruktur und ihre verwendung
ATE316523T1 (de) Benzoxazinderivate als 5-ht6-modulatoren und deren verwendungen
ATE362469T1 (de) 2,7-disubstituierteindole und ihre verwendung als 5-ht6 modulatoren
DE60322551D1 (de) 2,4-substituierte indole und deren verwendung als 5-ht6 modulatoren
ATE419248T1 (de) Phenylsubstituierte 4-hydroxy-tetrahydropyridone und ihre verwendung als schädlingsbekämpungsmittel und herbizide
ATE247109T1 (de) Substituierte benzoylisoxazole und ihre verwendung als herbizide
DE60009911D1 (de) Aminothiazolderivate und ihre verwendung als crf-rezeptor-liganden
ATE221529T1 (de) Oxadiazolinderivate und ihre verwendung als insektizide
DE50008549D1 (de) Triazolotriazinone und ihre verwendung
DE69917777D1 (de) Benzazol-verbindungen und ihre verwendung
DE60116732D1 (de) Isothiazol-derivate und ihre verwendung als schädlingsbekämpfungsmittel
ATE229016T1 (de) Substituierte heterocyclische benzocycloalkene und ihre verwendung als analgetisch wirksame substanzen
DE69821988D1 (de) Substituierte isochinoline derivate und ihre verwendung als anticonvulsiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1240164

Country of ref document: EP

EEFA Change of the company name